The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types.
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may often only indicate exposure to the virus, not protections against reinfection.
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic.
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded with significant reductions in transmission of the SARS-CoV-2 virus and reduced community mobility, both in the U.S. and globally, providing evidence that social distancing is a useful tool in preventing further spread of COVID-19.
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent’s anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma. Study showed 93% of patients responded with 67% achieving complete response.
A study led by The University of Texas MD Anderson Cancer Center has found that myelin is surprisingly dynamic, a discovery that has implications for treatment of multiple sclerosis and a type of myelin damage caused by some chemotherapy drugs, often referred to as “chemobrain.”
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.
MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer’s and other neurodegenerative diseases.
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress.
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.
Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.
Patients who had acupuncture during radiation reported less dry mouth symptoms up to 12 months after treatment
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.
MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.
Ziopharm and MD Anderson have announced a new research and development agreement to develop novel T-cell therapies using engineered T-cell receptors for solid tumors.
The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.
The North Texas A Conversation With a Living Legend® will honor Los Angeles Dodgers starting pitcher Clayton Kershaw in an interview with CBS News’ Bob Schieffer. The luncheon benefits the Moon Shots Program®.
An oncogene, UPS21, has been confirmed as a frequently amplified gene in pancreatic ductal adenocarcinoma, the most common and often lethal form of pancreatic cancer. The discovery could lead to new treatment options.